Release Date: 23-Jan-2025
BAT-7104 is a promising next-generation bispecific monoclonal antibody developed by Biothera. This innovative drug candidate targets both the PD-1/PD-L1 and CD47/SIRP-andalpha; immune checkpoint pathways, which play significant roles in immune evasion by tumors. By inhibiting these two pathways simultaneously, BAT-7104 aims to enhance the immune system's ability to recognize and destroy tumor cells while minimizing potential toxicity to healthy tissues.
Download Report: https://www.kuickresearch.com/ccformF.php?t=1737625307
The PD-1/PD-L1 pathway is a crucial immune checkpoint that tumors exploit to suppress T cell activation, allowing cancer cells to escape immune surveillance. By targeting PD-L1, BAT-7104 blocks this immune suppression, promoting T cell activation and enhancing the body’s immune response against the tumor. In addition to targeting the PD-1/PD-L1 axis, BAT-7104 also blocks the CD47/SIRP-andalpha; pathway. CD47, often referred to as a "don't eat me" signal, is expressed on the surface of many cells, including tumor cells. By binding to CD47, BAT-7104 prevents this inhibitory signal and triggers macrophages to phagocytize the tumor cells, thereby promoting immune-mediated tumor cell clearance.
A key advantage of BAT-7104 is its ability to preferentially bind to PD-L1-expressing tumor cells while sparing normal cells. Unlike some other anti-CD47 antibodies, BAT-7104 does not bind to CD47 on red blood cells, reducing the risk of toxicity that has been observed in clinical trials of other CD47-targeting therapies. This selective binding enhances the safety profile of the drug, making it a promising candidate for treating advanced malignancies.
BAT-7104 is currently undergoing Phase 2 clinical trials for advanced malignant tumors. Its dual inhibition of both the PD-1/PD-L1 and CD47/SIRP-andalpha; pathways offers a novel approach to cancer immunotherapy, with the potential to improve treatment outcomes for patients with cancers that are resistant to current therapies. If successful, BAT-7104 could represent an important advancement in the fight against cancer.